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Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, PAIn late 2010 a new class of oral anticoagulants, now known as the di-
rect oral anticoagulants (DOACs), was introduced in the United States,
as an alternative to vitamin K antagonists (VKAs), for the prevention
of thromboembolic events in patients with nonvalvular atrial ﬁbrilla-
tion. Subsequently these drugs were also shown to be safe and effective
in the prevention and treatment of venous thromboembolism. [1-4].
The direct thrombin inhibitor dabigatran etexilate was the ﬁrst agent
to be approved, followed by the factor Xa (FXa) inhibitors rivaroxaban,
apixaban, and edoxaban. TheseDOAC agents have demonstrated similar
or superior efﬁcacy to that of VKAs such as warfarin for the prevention
of stroke in patients with nonvalvular atrial ﬁbrillation, and similar efﬁ-
cacy for the treatment of venous thromboembolism in clinical trials [5].
The DOACs also offer clear advantages over warfarin, such as ﬁxed dos-
ing, fewer drug–drug interactions, and administrationwithout the need
for routine monitoring via coagulation tests [6]. With all anticoagulant
therapies, bleeding risks are an ongoing safety concern, but overall
risks of major bleeding with DOACs seem to be similar to or better
than that of warfarin [5,7,8]. Furthermore, the risk of intracranial hem-
orrhage is signiﬁcantly reduced, and there may be a slightly increased
risk of gastrointestinal bleeding [5,7,8].
Fortunately, because of the short half-lives of the DOACs, the major-
ity of DOAC-associated bleeding complications can be managed simply
by withholding the agent and providing supportive care for the patient.
[6]. Similarly, the short half-lives of the DOACs facilitate the timing of
elective surgery after the withdrawal of the agent [1-4]. However, ur-
gent reversal of the anticoagulant effect of a DOAC is required in rare
clinical situations, such as uncontrolled or life-threatening bleeding or
when an emergency invasive procedure is required.
Until recently, management of such situations was complicated by
the lack of speciﬁc reversal agents. This has changed, however, with
the introduction of DOAC-speciﬁc reversal agents. The dabigatran-
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cines Agency in November 2015, for use in the rare instances when
the reversal of the anticoagulant effects of dabigatran is needed (ie, for
emergency surgery and urgent procedures, or if there is life-
threatening or uncontrolled bleeding) [9,10]. Two other speciﬁc rever-
sal agents, andexanet alfa (r-Antidote, PRT064445; Portola Pharmaceu-
ticals, South San Francisco, Calif) and ciraparantag (aripazine, PER-977;
Perosphere, Danbury, Conn) are currently in development.
Andexanet alfa is an FXa decoy molecule with no intrinsic coagulation
activity that has been shown to reverse the effects of direct and indirect
FXa inhibitors in studies involving nonbleeding volunteers [11-13].
Ciraparantag is a potential antidote for direct and indirect FXa inhibitors
and direct thrombin inhibitors, as well as unfractionated heparin and
low-molecular-weight heparins such as enoxaparin, and thus is being
developed as a “universal agent” [14]. It is hoped that these agents
will streamline the management of patients who require urgent rever-
sal of the anticoagulant effects of DOACs in the emergency settings of
life-threateningbleeds, or as in the case of idarucizumab, both emergen-
cy surgery or life-threatening bleeds.
This special issue of The American Journal of Medicine provides infor-
mation and clinical guidance on the rationale for speciﬁc reversal agents
and their appropriate use. Clinical data on DOAC-associated bleeding
from phase 3 clinical trials and postmarketing trials are reviewed, as
are current strategies for the management and assessment of bleeding
events, perioperative management in the setting of DOAC therapy,
and reinitiation of DOAC therapy after a bleeding event. Current data re-
lating to themode of action, efﬁcacy, and safety of each of the agents are
also provided, alongside a review of the potential place for these agents
in guidelines and hospital protocols.
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